
\begin{table}[htb]\centering
\caption{Logit Marginal Effects\\Dependent variable: Generous PPM}
\begin{tabular}{l*{8}c}

 & (1) & (2) & (3) & (4) & (5) & (6) & (7) & (8)  \\
 & All & All & All & All (clustered SE) & Recent & Recent & Recent & Recent (clustered SE)  \\

                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\

\hline

       &               &               &               &               &               &               &               &               \\
Trial start year    &      0.0027***&      0.0027***&      0.0027***&      0.0029***&      0.0042***&      0.0042***&      0.0042***&      0.0045***\\
                    &    (0.0001)   &    (0.0001)   &    (0.0001)   &    (0.0002)   &    (0.0002)   &    (0.0002)   &    (0.0002)   &    (0.0003)   \\
\shortstack[l]{Phase 2 Clinical\\(includes Phase 2/Phase 3 trials)}&      0.0111***&               &      0.0107***&      0.0115** &      0.0135***&               &      0.0129***&      0.0138***\\
                    &    (0.0013)   &               &    (0.0013)   &    (0.0035)   &    (0.0015)   &               &    (0.0015)   &    (0.0036)   \\
Phase 3 Clinical    &      0.0162***&      0.0161***&      0.0153***&      0.0166*  &      0.0181***&      0.0180***&      0.0171***&      0.0185*  \\
                    &    (0.0019)   &    (0.0019)   &    (0.0019)   &    (0.0073)   &    (0.0021)   &    (0.0021)   &    (0.0021)   &    (0.0074)   \\
Trial site in US=1  &      0.0056***&      0.0055***&      0.0054***&      0.0056***&      0.0062***&      0.0060***&      0.0061***&      0.0062***\\
                    &    (0.0013)   &    (0.0013)   &    (0.0013)   &    (0.0016)   &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0018)   \\
Drug indication for neoplasm&      0.1096***&      0.1093***&      0.1173***&      0.1207***&      0.1149***&      0.1146***&      0.1259***&      0.1294*** \\
                    &    (0.0011)   &    (0.0011)   &    (0.0013)   &    (0.0030)   &   (0.0012)   &    (0.0012)   &      0.1259***&      0.1294*** \\
Received NIH funding&     -0.0060*  &     -0.0060*  &     -0.0042   &     -0.0043***&     -0.0079** &     -0.0079** &     -0.0056*  &     -0.0058***\\
                    &    (0.0025)   &    (0.0025)   &    (0.0025)   &    (0.0006)   &    (0.0029)   &    (0.0029)   &    (0.0028)   &    (0.0008)   \\
Biomarker type: genomic&      0.1881***&      0.1881***&      0.1884***&      0.1976***&      0.1947***&      0.1946***&      0.1951***&      0.2043***\\
                    &    (0.0025)   &    (0.0025)   &    (0.0025)   &    (0.0102)   &    (0.0028)   &    (0.0028)   &    (0.0028)   &    (0.0117)   \\
Phase 2 only        &               &      0.0114***&               &               &               &      0.0138***&               &               \\
                    &               &    (0.0013)   &               &               &               &    (0.0015)   &               &               \\
Phase 2/3 Clinical  &               &      0.0057   &               &               &               &      0.0067   &               &               \\
                    &               &    (0.0042)   &               &               &               &    (0.0046)   &               &               \\
N                   &      113410   &      113410   &      113410   &      106626   &       96254   &       96254   &       96254   &       90650   \\
* p$<$0.05, ** p$<$0.01, *** p$<$0.001 \\

\end{tabular}
\end{table}

